202 related articles for article (PubMed ID: 32994996)
1. Hybrid Fc-fused interleukin-7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy.
Kim JH; Kim YM; Choi D; Jo SB; Park HW; Hong SW; Park S; Kim S; Moon S; You G; Kang YW; Park Y; Lee BH; Lee SW
Clin Transl Immunology; 2020; 9(9):e1168. PubMed ID: 32994996
[TBL] [Abstract][Full Text] [Related]
2. rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors.
Lee M; Im SK; Baek S; Ji M; Kim M; Lee EJ; Ji ST; Ferrando-Martinez S; Wolfarth A; Lee JY; Kim D; Choi D
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38471713
[TBL] [Abstract][Full Text] [Related]
3. IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy.
Lee KJ; Choi D; Tae N; Song HW; Kang YW; Lee M; Moon D; Oh Y; Park S; Kim JH; Jeong S; Yang J; Park U; Hong DH; Byun MS; Park SH; Sohn J; Park Y; Im SK; Choi SS; Kim DH; Lee SW
Cell Rep Med; 2024 May; 5(5):101567. PubMed ID: 38744277
[TBL] [Abstract][Full Text] [Related]
4. Compassionate use of recombinant human IL-7-hyFc as a salvage treatment for restoring lymphopenia in patients with recurrent glioblastoma.
Ahn S; Park JS; Kim H; Heo M; Sung YC; Jeun SS
Cancer Med; 2023 Mar; 12(6):6778-6787. PubMed ID: 36583472
[TBL] [Abstract][Full Text] [Related]
5. Fc-fused IL-7 provides broad antiviral effects against respiratory virus infections through IL-17A-producing pulmonary innate-like T cells.
Kwon DI; Park S; Jeong YL; Kim YM; Min J; Lee C; Choi JA; Choi YH; Kong HJ; Choi Y; Baek S; Lee KJ; Kang YW; Jeong C; You G; Oh Y; Im SK; Song M; Kim JK; Chang J; Choi D; Lee SW
Cell Rep Med; 2024 Jan; 5(1):101362. PubMed ID: 38232693
[TBL] [Abstract][Full Text] [Related]
6. A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity.
Kim MY; Jayasinghe R; Devenport JM; Ritchey JK; Rettig MP; O'Neal J; Staser KW; Kennerly KM; Carter AJ; Gao F; Lee BH; Cooper ML; DiPersio JF
Nat Commun; 2022 Jun; 13(1):3296. PubMed ID: 35697686
[TBL] [Abstract][Full Text] [Related]
7. A single administration of hIL-7-hyFc induces long-lasting T-cell expansion with maintained effector functions.
Kim S; Lee SW; Koh JY; Choi D; Heo M; Chung JY; Lee BH; Yang SH; Sung YC; Lee H; Shin EC; Park SH
Blood Adv; 2022 Dec; 6(23):6093-6107. PubMed ID: 36206199
[TBL] [Abstract][Full Text] [Related]
8. Understanding the pharmacokinetic journey of Fc-fusion protein, rhIL-7-hyFc using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA.
Kim A; Oh MS; Lee GH; Song S; Byun MS; Choi D; Yu BY; Lee H
Antib Ther; 2024 Apr; 7(2):105-113. PubMed ID: 38566969
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
[TBL] [Abstract][Full Text] [Related]
10. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
11. Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity.
Seclì L; Infante L; Nocchi L; De Lucia M; Cotugno G; Leoni G; Micarelli E; Garzia I; Avalle L; Sdruscia G; Troise F; Allocca S; Romano G; Scarselli E; D'Alise AM
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37117006
[TBL] [Abstract][Full Text] [Related]
12. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy.
Lauret Marie Joseph E; Kirilovsky A; Lecoester B; El Sissy C; Boullerot L; Rangan L; Marguier A; Tochet F; Dosset M; Boustani J; Ravel P; Boidot R; Spehner L; Haicheur-Adjouri N; Marliot F; Pallandre JR; Bonnefoy F; Scripcariu V; Van den Eynde M; Cornillot E; Mirjolet C; Pages F; Adotevi O
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230108
[TBL] [Abstract][Full Text] [Related]
13. An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.
Xu Y; Carrascosa LC; Yeung YA; Chu ML; Yang W; Djuretic I; Pappas DC; Zeytounian J; Ge Z; de Ruiter V; Starbeck-Miller GR; Patterson J; Rigas D; Chen SH; Kraynov E; Boor PP; Noordam L; Doukas M; Tsao D; Ijzermans JN; Guo J; Grünhagen DJ; Erdmann J; Verheij J; van Royen ME; Doornebosch PG; Feldman R; Park T; Mahmoudi S; Dorywalska M; Ni I; Chin SM; Mistry T; Mosyak L; Lin L; Ching KA; Lindquist KC; Ji C; Londono LM; Kuang B; Rickert R; Kwekkeboom J; Sprengers D; Huang TH; Chaparro-Riggers J
Cancer Immunol Res; 2021 Oct; 9(10):1141-1157. PubMed ID: 34376502
[TBL] [Abstract][Full Text] [Related]
14. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
15. Tumors establish resistance to immunotherapy by regulating T
Marshall LA; Marubayashi S; Jorapur A; Jacobson S; Zibinsky M; Robles O; Hu DX; Jackson JJ; Pookot D; Sanchez J; Brovarney M; Wadsworth A; Chian D; Wustrow D; Kassner PD; Cutler G; Wong B; Brockstedt DG; Talay O
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243932
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts.
Murphy WJ; Back TC; Conlon KC; Komschlies KL; Ortaldo JR; Sayers TJ; Wiltrout RH; Longo DL
J Clin Invest; 1993 Oct; 92(4):1918-24. PubMed ID: 8408644
[TBL] [Abstract][Full Text] [Related]
17. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
[TBL] [Abstract][Full Text] [Related]
18. Enriching CCL3 in the Tumor Microenvironment Facilitates T cell Responses and Improves the Efficacy of Anti-PD-1 Therapy.
Kang TG; Park HJ; Moon J; Lee JH; Ha SJ
Immune Netw; 2021 Jun; 21(3):e23. PubMed ID: 34277113
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
20. Natural form of noncytolytic flexible human Fc as a long-acting carrier of agonistic ligand, erythropoietin.
Im SJ; Yang SI; Yang SH; Choi DH; Choi SY; Kim HS; Jang DS; Jin KS; Chung YK; Kim SH; Paik SH; Park YC; Chung MK; Kim YB; Han KH; Choi KY; Sung YC
PLoS One; 2011; 6(9):e24574. PubMed ID: 21957455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
